Skip to content
Blerp – Lifestyle
Author:
Larimar Therapeutics
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
June 26, 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
May 14, 2026
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
April 30, 2026
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
March 4, 2026